Tonix Pharmaceuticals Enrolls First Patient in HORIZON Study
Tonix Pharmaceuticals announced that the first patient has been enrolled in HORIZON, a potentially pivotal Phase 2 study evaluating TNX-102 SL 5.6 mg as a first-line monotherapy in adults with major depressive disorder.
